Showing results (111-120 of 253) with videos related to

Sort By:
Pageof 26
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Transfusion|February 8, 2019
Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignanciesSherilyn A Tuazon, Ang Li, Theodore Gooley, et al.
Human Gene Therapy|December 21, 2006
Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophyZejing Wang, James M Allen, Stanley R Riddell, et al.
Blood|June 8, 2013
CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemiaMargaret L Green, Wendy M Leisenring, Hu Xie, et al.
Cancer Immunology Research|October 31, 2014
Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cellsCarolina Berger, Daniel Sommermeyer, Michael Hudecek, et al.
Blood|July 5, 2003
Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivationMorgan Hakki, Stanley R Riddell, Jan Storek, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 4, 2017
Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell ProductsKenneth Cornetta, Lisa Duffy, Cameron J Turtle, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 25, 2019
Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen ReceptorsAshwini Balakrishnan, Anusha Rajan, Alexander I Salter, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Pageof 26